Companies › ESLA

ESTRELLA IMMUNOPHARMA INC (ESLA)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001844417 · EDGAR filings · Updated 2026-06-30

ESTRELLA IMMUNOPHARMA INC (ESLA) has reported institutional ownership of 12.1%, with 16 institutional managers holding positions valued at $5.49M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-06-30 — Current report (8-K) filed
• 2026-05-27 — Proxy statement (DEF 14A) filed
• 2026-05-18 — Quarterly report (10-Q) filed
• 2026-05-18 — Late-filing notice for quarterly report (NT 10-Q)
• 2026-05-15 — SCHEDULE 13G filed
• 2026-04-30 — 10-K/A filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ESTRELLA IMMUNOPHARMA INC has 16 institutional holders and institutional ownership of 12.1%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 0 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

Natural Alternatives International Inc (NAII) · Vivani Medical Inc (VANI) · IN8BIO INC (INAB) · ACTINIUM PHARMACEUTICALS INC (ATNM) · Lisata Therapeutics Inc (LSTA) · PAVmed Inc (PAVM)